Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA
- PMID: 19366348
- PMCID: PMC2697810
- DOI: 10.1111/j.1476-5381.2009.00148.x
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA
Abstract
Antisense oligonucleotides and small interfering RNA have enormous potential for the treatment of a number of diseases, including cancer. However, several impediments to their widespread use as drugs still have to be overcome: in particular their lack of stability in physiological fluids and their poor penetration into cells. Association with or encapsulation within nano- and microsized drug delivery systems could help to solve these problems. In this review, we describe the progress that has been made using delivery systems composed of natural or synthetic polymers in the form of complexes, nanoparticles or microparticles.
Figures




Similar articles
-
Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.Biomed Pharmacother. 2006 Nov;60(9):607-20. doi: 10.1016/j.biopha.2006.07.093. Epub 2006 Aug 31. Biomed Pharmacother. 2006. PMID: 16952435 Review.
-
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.Int J Pharm. 2008 Dec 8;364(2):237-48. doi: 10.1016/j.ijpharm.2008.06.011. Epub 2008 Jun 19. Int J Pharm. 2008. PMID: 18619528 Review.
-
Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.Mol Pharm. 2021 Apr 5;18(4):1491-1506. doi: 10.1021/acs.molpharmaceut.0c01238. Epub 2021 Mar 18. Mol Pharm. 2021. PMID: 33734715 Free PMC article. Review.
-
Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.Eur J Pharm Biopharm. 2009 Mar;71(3):490-504. doi: 10.1016/j.ejpb.2008.09.024. Epub 2008 Nov 1. Eur J Pharm Biopharm. 2009. PMID: 18977435 Review.
-
Oral delivery of siRNA and antisense oligonucleotides.J Drug Target. 2009 Aug;17(7):491-5. doi: 10.1080/10611860903057674. J Drug Target. 2009. PMID: 19530907
Cited by
-
Editors' pick 2009.Br J Clin Pharmacol. 2010 Feb;69(2):107-10. doi: 10.1111/j.1365-2125.2009.03606.x. Br J Clin Pharmacol. 2010. PMID: 20233172 Free PMC article. No abstract available.
-
Protein kinase Cα downregulation via siRNA-PKCα released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells.Int J Nanomedicine. 2011;6:1303-11. doi: 10.2147/IJN.S19405. Epub 2011 Jun 22. Int J Nanomedicine. 2011. PMID: 21753881 Free PMC article.
-
Controlled Release of Nor-β-lapachone by PLGA Microparticles: A Strategy for Improving Cytotoxicity against Prostate Cancer Cells.Molecules. 2016 Jul 2;21(7):873. doi: 10.3390/molecules21070873. Molecules. 2016. PMID: 27384551 Free PMC article.
-
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12. Cancer Lett. 2012. PMID: 22050909 Free PMC article.
-
Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.Molecules. 2017 Oct 13;22(10):1724. doi: 10.3390/molecules22101724. Molecules. 2017. PMID: 29027965 Free PMC article. Review.
References
-
- Agrawal S. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta. 1999;1489:53–68. - PubMed
-
- Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995;28:7–16. - PubMed
-
- Akhtar S, Lewis KJ. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm. 1997;151:57–67.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources